Skip to main content
OpenTrials
Completed

NCT Number: NCT06710990

Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer

The study is being conducted to evaluate the pharmacokinetics and safety of SHR-A1811 monotherapy and in combination with Ritonavir or Itraconazole in subjects with HER2-expressing advanced breast cancer.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1

Primary location

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ECOG score of 0 or 1;
  • Expected survival of not less than 3 months;
  • Important organ functions meet the following criteria:
  • Absolute neutrophil count (ANC) ≥1.5×109/L (1,500/mm3);
  • Platelet count (PLT) ≥100×109/L (100,000/mm3);
  • Hemoglobin (Hgb) ≥9.0 g/dL (90g/L);
  • Albumin level ≥3.0 g/dL;
  • Total serum bilirubin ≤1.5× the upper limit of normal (ULN);
  • Prothrombin time and activated partial thromboplastin time (aPTT) ≤1.5×ULN;
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (for patients with liver metastasis, ALT and AST ≤5×ULN);
  • Serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL/min;
  • QTcF ≤470 msec;
  • Left ventricular ejection fraction (LVEF) ≥50%.

Exclusion criteria

  • Known active central nervous system metastases that have not been treated with surgery or radiation, except those that have been stable for at least 1 month after treatment and have discontinued corticosteroids for >2 weeks;
  • Having cardiac diseases, such as severe/unstable angina, symptomatic congestive heart failure (NYHA II-IV), clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention, myocardial infarction within 6 months before the first administration, etc.
  • Known severe allergic history to any component of the SHR-A1811 product (ADC, total antibody, unconjugated toxin SHR169265 or its excipients), or hypersensitivity to humanized monoclonal antibody products (such as trastuzumab, pertuzumab, etc.);
  • Having contraindications to ritonavir or itraconazole use;
  • Having one or more factors that affect oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction, partial or total gastrectomy, etc.), or having active gastrointestinal diseases or other diseases that may significantly affect drug absorption, distribution, metabolism, or excretion.

Treatment and study plan

SHR-A1811

Drug

SHR-A1811

Ritonavir

Drug

Ritonavir

Itraconazole

Drug

Itraconazole

Primary outcomes

  1. The maximum concentration (Cmax) for SHR-A1811

    Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.

  2. The maximum concentration (Cmax) for payload

    Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.

  3. Area under the concentration curve from time 0 to 16 days (AUC0-16d) for SHR-A1811

    Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.

  4. Area under the concentration curve from time 0 to 16 days (AUC0-16d) for payload

    Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.

Secondary outcomes

  1. Time to maximum plasma concentration (Tmax)

    Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.

  2. Terminal half-life (t1/2)

    Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.

  3. Area under the concentration curve from time 0 to infinity (AUCinf)

    Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.

  4. Clearance (CL)

    Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.

  5. Volume of distribution at steady state (Vss)

    Time frame: Cycle 2 and Cycle 3. Each cycle is 21 days.

  6. Incidence and severity of adverse events

    Time frame: From the beginning of screening period to approximately 3 months after the last dose.

Sponsors and collaborators

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd.

Industry

Registry information

Official study title

A Multicenter, Open-label, Fixed-sequence Study to Evaluate Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Dec 2, 2024
Registry last updated
Jun 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.